Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Therapeutic effect and underlying mechanism of cell therapy on cyclophosphamide-induced premature ovarian insufficiency mouse model

ABSTRACT: An equivalent dosage of human umbilical cord-derived mesenchymal stem cell (HucMSC), adipose tissue-derived mesenchymal stem cell (ADSC), and SVF was orthotopically administered into a cyclophosphamide (CTX)-induced premature ovarian insufficiency (POI) mouse model. The therapeutic impacts were meticulously evaluated employing a suite of assays. The underlying mechanisms were investigated through RNA sequencing (RNA-seq) and mass spectrometry, offering insights into the cellular and molecular responses.

ORGANISM(S): Homo Sapiens

SUBMITTER: Songying Zhang

PROVIDER: PXD064540 | iProX | Sat May 31 00:00:00 BST 2025

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Comparison of the therapeutic effects between stem cells and exosomes in primary ovarian insufficiency: As promising as cells but different persistency and dosage.

Project description:Primary ovarian insufficiency (POI) refers to the loss of ovarian function under the age of 40 and results in amenorrhea and infertility. Our previous studies have shown that transplantation of mesenchymal stem cells (MSCs) and MSC-derived exosomes in chemotherapy-induced POI mouse ovaries can reverse the POI and eventually achieve pregnancy. Based on our recent studies, MSC-derived exosomes have almost equal therapeutic potentials as transplanted MSCs. However, it is still unclear whether exosomes can completely replace MSCs in POI treatment. In this study, we induced POI in C57/BL6 mice by chemotherapy (CXT) using a standard protocol. We compared the RNA expression pattern in ovarian tissue after MSC or exosome treatment. our data suggest that a minimal 10-fold increase, and ideally 100-fold increase, in the exosome concentration is required to generate more analogous results to MSC treatment.

2023-05-30 | GSE233743 | GEO

Identify urinary exosome microRNAs that are unique to premature ovarian insufficiency

Project description:This study is to identify urinary exosome microRNAs (miRNAs) that are unique to premature ovarian insufficiency (POI) with and without Turner syndrome and to use them as diagnostic markers for POI patients. We examined the miRNAexpression profile in urine exosomes from POI patients with and without Turner syndrome.

2022-09-28 | GSE205700 | GEO

BCAA insufficiencies lead to premature ovarian insufficiency via ceramide induced elevation of ROS

Project description:Premature ovarian insufficiency (POI) is a disease featured by early menopause before 40 years of age, accompanied by an elevation of follicle-stimulating hormone (FSH). Though POI affects many aspects of women’s health, its major causes remain unknown. Many clinical studies have shown that POI patients are generally underweight, indicating a potential correlation between POI and metabolic disorders. To understand the pathogenesis of POI, we performed metabolomics analysis on serum and identified branch chain amino acid (BCAA) insufficiency related metabolic disorders in two independent cohorts from two clinics. A low BCAA diet phenotypically reproduced the metabolic, endocrine, ovarian, and reproductive changes of POI in young C57 B6 mice. A mechanism study revealed that the BCAA insufficiency induced POI is associated with abnormal activation of the ceramide-ROS axis and consequent impairment of ovarian granulosa cell function. Significantly, dietary supplement of BCAA prevented the development of ROS-induced POI in female mice. The results of this pathogenic study will lead to the development of specific therapies for POI.

2023-03-28 | GSE215358 | GEO

Homozygosity mapping in family segregating premature ovarian insufficiency (POI)

Project description:Premature ovarian insufficiency (POI) is defined as a primary ovarian defect characterized by absent menarche (primary amenorrhea) or premature depletion of ovarian follicles before the age of 40 (secondary amenorrhea) with hypergonadotropism and hypoestrogenism. Premature ovarian insufficiency has few known genetic causes but in familial cases a genetic link is often suspected. A large consanguineous family with three female affected with POI was investigated. All samples including 3 affected and 5 unaffecd underwent whole genome SNP genotyping using Affymetric Axiom_GW_Hu_SNP array. Linkage analysis was carried out using HomozygosityMapper and Allegro softwares.Linkage analysis mapped the disease phenotype to long arm of chromosome 20. Sequence data analysis of potential candidate genes failed to detect any pathogenic variant.

2014-03-20 | GSE56043 | GEO

Homo sapiens

Project description:Homozygosity mapping in family segregating premature ovarian insufficiency (POI)

| PRJNA242288 | ENA

HEP14-activated PKC-ERK1/2 pathway boosts HEP14-empowered hADSCs for ovarian regeneration and functional restoration

Project description:Ovarian insufficiency (OI), including both premature ovarian insufficiency (POI) and age-related natural-aging ovarian insufficiency (ARNA-OI), significantly affects women’s health and remains persistent challenge in clinical treatment. In this study, bulk and scRNA-sequencing analysis indicated that HEP14 alters gene expression patterns in hADSCs and promotes the survival, antifibrotic, and proangiogenic capabilities, as well as the transdifferentiation potential of hADSCs. The key factors involved in these processes were upregulated by the HEP14-activated PKC-ERK1/2 signaling pathway. In both doxorubicin-induced POI and age-related natural-aged ARNA-OI mouse models, the combined administration of h-hADSCs and HEP14 encapsulated in PLGA microspheres (HEP14/PLGA) substantially enhanced ovarian regeneration and restoration of gonadal hormone levels through autocrine, paracrine, or endocrine mechanisms. Importantly, this combined therapy markedly improved the fertility of POI mice. These results demonstrate that the therapeutic potential of this combined therapy for POI and ARNA-OI, opening new avenues for clinical research and treatment strategies.

2025-07-17 | GSE273950 | GEO

HEP14-activated PKC-ERK1/2 pathway boosts empowered-hADSCs for ovarian regeneration and functional restoration [RNA-seq]

2025-07-17 | GSE273949 | GEO

Differences in miRNA expression profiles of follicular fluid exosomes between Premature ovarian insufficiency and normal ovarian reserve

Project description:Premature ovarian insufficiency (POI) refers to the severe decline and failure of ovarian function in women before the age of 40, and current treatment methods have significant limitations. In order to screen miRNAs with good anti-apoptotic effect, we used high-throughput sequencing technology to study the differences in exosomal miRNA expression profiles from human follicular fluid between patients with POI and patients with normal ovarian reserve.

2024-12-01 | GSE253684 | GEO

RNA-Seq Facilitates Quantitative Analysis of Wild Type and Bnc1tr/tr ovary Transcriptomes

Project description:Primary ovarian insufficiency (POI) is a clinical syndrome of ovarian dysfunction characterized by premature exhaustion of primordial follicles. POI causes infertility, serious daily life disturbances and long-term health risks. However, the underlying mechanism remains largely unknown. We have previously identified Basonuclin1 (BNC1) mutation from a large Chinese POI pedigree and find the targeted Bnc1 mutation mouse exhibites POI. In this study, we find that BNC1 plays a key role in the dynamic balance of ovarian reserve, and maintaining lipid metabolism and redox homeostasis in oocytes during follicular development. Deficiency of BNC1 results in premature follicular activation and accelerated follicular atresia, but doesn’t affect the ovarian primordial follicle reserve. Mechanistically, BNC1 targets the NF2-YAP pathway to trigger oocyte ferroptosis. Inhibition of ferroptosis significantly rescues POI. These findings uncover a novel pathologic mechanism of POI based on BNC1 deficiency and is the first report showing ferroptosis involved in oocyte death.

2022-08-31 | GSE194196 | GEO

Genome-wide maps of chromatin state in Wild Type mouse ovary

2022-08-31 | GSE194195 | GEO